X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The partnership will initially focus on the development and evaluation of mRNA vaccine formulations against human immunodeficiency virus (HIV), with the objective of identifying a lead formulation to move forward to clinical development.
Lead Product(s): mRNA vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: eTheRNA immunotherapies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 04, 2021
Details:
The vaccine construct consists of conserved immunoreactive regions from external and internal coronavirus proteins, from each virus genus, encoded in mRNA. The mRNA constructs will be formulated with Lawrence Livermore National Laboratory 's NLP vehicle prior to injection.
Lead Product(s): Coronavirus vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Lawrence Livermore
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 19, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
